- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Spironolactone 100mg, Placebo oral capsule
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 105
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ventricular Arrhythmias
- Interventions
- spironolactone, placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Thoracic Aortic Aneurysm
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertension
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- ADPKD
- Interventions
- Spironolactone, Sugar pill
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End-Stage Renal Disease
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Pharmacological Treatment
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
- Conditions
- Right Heart Failure, Pulmonary Hypertension
- Interventions
- Spironolactone and conivaptan
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Congenital Disorders
- Interventions
- Spironolactone (drug)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Type 2 Diabetes Mellitus, Vascular Disease
- Interventions
- Spironolactone, Hydrochlorothiazide + potassium, Placebo
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myocardial Fibrosis, Hypertrophic Cardiomyopathy
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
- Interventions
- phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone, phase 2B Chlorthalidone LD + Spironolactone LD
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
- Interventions
- Spironolactone 25mg, Placebo
- Drug · Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hypoglycemia, Healthy
- Interventions
- Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Spironolactone and patiromer
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease
- Interventions
- Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Bypass Graft, Angiotensin Receptor Blockers, Spironolactone, Aspirin, Clopidogrel, Surgical Ventricular Restoration
- Drug · Procedure
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Alcohol Use Disorder, Hiv
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- End Stage Renal Disease, Hemodialysis
- Interventions
- Spironolactone, L-arginine, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Female Androgenetic Alopecia
- Interventions
- 5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 60 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
- Interventions
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Drug
- Lead sponsor
- James A. Tumlin, MD
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Lawrenceville, Georgia • Bethlehem, Pennsylvania
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Spironolactone, Standard care
- Drug · Other
- Lead sponsor
- Uppsala University
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 38
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more